Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quanduzhong Capsule for Primary Osteoporosis (Kidney-Yang Deficiency Type)
ChiCTR2100050932Phase 4Recruiting
- Sponsor
- 中国中医科学院望京医院
- Start
- Sep 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Quanduzhong in involutional osteoporosis, osteoporosis and senile osteoporosis (3 arms), sponsored by 中国中医科学院望京医院. Primary endpoint: Clinical symptom grading quantitative score. Started Sep 2021; status: recruiting.
02
Drugs
Quanduzhong
03
Conditions
involutional osteoporosisosteoporosissenile osteoporosis
Beyond the preview
Go deeper on ChiCTR2100050932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050932.